Fig. 4From: Effects of Sacubitril/Valsartan on biomarkers of fibrosis and inflammation in patients with heart failure with reduced ejection fractionSerum PICP: Type 1 procollagen C-terminal propeptide (PICP) and Human cartilage glycoprotein-39 (YKL-40) at baseline and after 30 and 60 days of S/V treatment. Means ± se; **p < 0.01 versus baselineBack to article page